<DOC>
	<DOCNO>NCT02412436</DOCNO>
	<brief_summary>This study do evaluate effect HIV TB treatment commonly use birth control method . This study do woman infect HIV TB take efavirenz ( EFV ; Sustiva® ; anti-HIV medication ) , rifampicin ( RIF ; anti-TB medication ) isoniazid ( INH ; anti-TB medication ) . The purpose study find best schedule give depot medroxyprogesterone acetate ( DMPA ; hormonal birth control method give shot every 3 month ) woman HIV TB also take EFV RIF . This study also try find 150 mg injection DMPA effective preventing ovulation , process ovary ( ovary part female reproductive system ) release egg fertilization , 12 week woman take EFV RIF . Another purpose study find safe take RIF , EFV DMPA time .</brief_summary>
	<brief_title>PK Study Rifampicin Interactions With DMPA Efaviranz TB</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<criteria>HIV1 infection Current tuberculosis infection , confirm probable diagnosis Currently stable EFVbased cART least 28 day Currently receive RIF Isoniazid ( INH ) base TB therapy least 5 day per week schedule completion intensive phase TB treatment ( minimum 8 week TB treatment ) expect TB treatment minimum 12 week enrollment Premenopausal female presume normal ovarian function base normal menstrual history absence previous ovarian dysfunction diagnosis Last menstrual period ( LMP ) ≤35 day prior study entry Negative serum urineHCG pregnancy test within 30 day prior study entry negative pregnancy test entry networkapproved laboratory operates accordance Good Clinical Practices participate appropriate external quality assurance program All participant must agree participate conception process ( eg , active attempt become pregnant vitro fertilization ) duration study . Women reproductive potential , participate sexual activity could lead pregnancy , must agree use additional reliable method contraception study . Acceptable form contraceptive include : Condoms ( male female ) without spermicidal agent Diaphragm cervical cap spermicide Nonhormonal IUD Bilateral tubal ligation Male partner vasectomy Laboratory value within 30 day prior study entry : Absolute neutrophil count ≥500 cells/mm3 Platelet count ≥50,000 platelets/mm3 Hemoglobin ≥8.0 g/dL Aspartate transaminase ( AST ) alanine aminotransferase ( ALT ) &lt; 5 x upper limit normal ( ULN ) Creatinine ≤1.5 x ULN Total bilirubin ≤2.0 x ULN Ability willingness provide write informed consent Receipt DMPA injectable contraceptive within 180 day prior study entry . Receipt hormonal contraceptive within 30 day prior study entry . Use drug RIF EFV know : 1 ) induce CYP3A4 system within 30 day 2 ) inhibit CYP3A4 system one week prior study entry . ≤40 kg weight . Bilateral oophorectomy Less 30 day postpartum study entry Hypersensitivity DMPA , MPA , ingredient DMPA . Breast cancer Serious illness require systemic treatment and/or hospitalization within 21 day prior study entry Karnofsky performance score &lt; 70 within 14 day prior study entry Use immunosuppressant medication include systemic corticosteroid within 30 day prior study entry Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement History deep venous thrombosis pulmonary embolus</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>46 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>